این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Iranian Journal of Pediatric Hematology and Oncology، جلد ۱۰، شماره ۴، صفحات ۲۴۱-۲۴۹
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Comparison of Magnetic Resonance Imaging T2 Results in Beta-Thalassemia Patients Treated by Deferasirox or Combination of Deferoxamine and Deferiprone
چکیده انگلیسی مقاله Background: Iron extra load is an anticipated and lethal consequence of chronic blood transfusion in major beta-thalassemia patients; therefore it is necessary to use an efficient iron chelator drug to stimulate the evacuation of the surplus iron from the body. This trial was performed to compare myocardial and hepatic magnetic resonance imaging T2 (MRI T2*) results of beta-thalassemia patients treated by Deferasirox or combination of Deferoxamine and Deferiprone. Material and Methods: In this clinical trial, 44 patients who were on combination therapy with Deferiprone and Deferoxamine and complied with the inclusion criteria were randomized to either case (Deferasirox) or control (combined therapy) groups. Twenty-two patients in the case group received Deferasirox. For 22 patients in the control group, prior treatment with Deferiprone and Deferoxamine was continued. Myocardial and hepatic MRI T2* results were assessed before and after the study. Moreover, serum ferritin level (SFL) was evaluated every 3 months. Results: SFL at the start of the study did not differ significantly in two groups (2158.1± 1012.2 μg/L in the control group vs. 2145.5±1121.4 μg/L in the case group) (P=0.08). SFL at the end of the study did not differ significantly in two groups (2204.4±1143.5 μg/L in the control group vs. 2347.2±1236.6 μg/L in the case group), either (P=0.12). In each group, myocardial and hepatic MRI T2 at the start and at the end of the trial did not differ significantly (P>0.1). Conclusion: Myocardial and hepatic MRI T2*results were better in the control (combination therapy) group than those in the case (Deferasirox) group. Major beta-thalassemia patients replied to combined treatment better than Deferasirox.
کلیدواژه‌های انگلیسی مقاله Beta-Thalassemia, Deferasirox , Deferiprone, Deferoxamine, Magnetic Resonance Imaging
نویسندگان مقاله | Narges Beygom Mirbehbahani
Cancer Research Center, Golestan University of Medical Sciences, Gorgan, Iran


| Ghazal Vaseghi
Hematology-Oncology Research Center, Taleghani Hospital, Golestan University of Medical Sciences, Gorgan, Iran


| Azam Rashidbaghan
Kermanshah University of Medical Sciences, Kermanshah, Iran.
Kermanshah University of Medical Sciences, Kermanshah, Iran

| Ali Vakili
Golestan University of Medical Sciences, Gorgan, Iran


| Azam Jahazi
Gorgan Branch, Islamic Azad University, Gorgan, Iran
Cancer Research Center, Golestan University of Medical Sciences, Gorgan, Iran.

نشانی اینترنتی http://ijpho.ssu.ac.ir/browse.php?a_code=A-10-705-1&slc_lang=en&sid=1
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده تخصصی
نوع مقاله منتشر شده پژوهشی
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات